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Abstract 
 The main determinants in toxin cell specificity are often interactions with surface receptors. It has 
recently been determined that the membrane phospholipid sphingomyelin (SM) is the primary receptor 
for the Helicobacter pylori vacuolating cytotoxin (VacA). While the cellular receptor has been identified, 
the molecular basis of SM recognition remains unknown. Molecular modeling of unrelated SM-binding 
proteins suggests that specific binding occurs through tryptophan rich aromatic clusters located in solvent 
exposed peptide loops between β-sheet domains. Structural comparison of these proteins with VacA led 
to the identification of a similar tryptophan containing aromatic cluster in the mid-region of the p55 
subunit of VacA. Additionally, sequence alignment of this putative binding site exhibited sequence 
homology with the phosphorylcholine binding site of another SM-binding toxin. In this study we tested 
the effects of mutating each of the 11 tryptophan residues in VacA. While mutating each of the 8 
tryptophan residues present in the auto-transporter p33 domain did not cause substantial attenuation in 
toxin activity, alanine substitution of 2 tryptophan residues within the putative binding site led to 
significant attenuation. Further, tryptophan to alanine mutation of W603, a residue present in the center of 
the putative binding site, was found to be attenuated in cell binding to human-derived AZ-521 gastric 
epithelial cells. Interestingly, a W603A mutation is also present within a vacA allele associated with a 
lessened propensity for gastric disease, decreased toxin binding, and differences in cell specificity. This 
thesis proposes a novel VacA-SM binding site and identifies a possible cause of allele associated 
differences in VacA pathogenicity.  
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Chapter 1: Introduction 
 This thesis discusses the characterization of the molecular bases of sphingomyelin 
binding by the Vacuolating cytotoxin (VacA) of H. pylori. As with any toxin, the first step in 
VacA intoxication is binding to the plasma membrane of eukaryotic cells (Garner et al. 1996).  
Along with providing a means of cell entry, the mechanism of cell binding plays a key role in 
determining cell sensitivity, tissue tropism, mode of internal transportation, and toxin activity, 
making it an important determinant in toxin pathogenicity and overall cellular outcome.  VacA is 
of particular interest as a model system for studying such interactions as a result of the diverse 
effects it has on varying cell types. In addition to this multifunctionality, VacA is the only known 
bacterial toxin to utilize the phospholipid sphingomyelin (SM) as a receptor, allowing for the 
investigation of a novel mechanism of toxin cell binding (Cover et al.2005, Gupta et al. 2010). 
Through the investigation of these interactions, a more thorough understanding of the structural 
motifs involved in binding can be achieved and subsequently applied to analogous systems. In 
this thesis, the importance of VacA cell binding as a model system and as a primary factor in H. 
pylori pathogenicity will be discussed. 
Infectious Disease 
 Infectious diseases are among the leading causes of death worldwide, with the majority of 
deaths occurring in developing countries. This problem is of growing severity due to widening 
transportation networks (Tatem et al. 2006) and the spread of antibiotic resistance (Versluis et al. 
1992, Davis et al. 1994, Zhang et al. 2011), which together have contributed to the broader and 
more rapid spread of pathogens which are resistant to pharmaceutical agents that were once most 
effective. These problems are of particular concern in gastrointestinal bacteria due to the 
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increased potential for horizontal gene transfer between bacteria in areas simultaneously 
colonized by multiple species (Devirgiliss et al. 2011, Megraud et al. 2004, Dorer et al. 2010). 
The growing demand for an alternative to antibiotics has increased the need for research which 
will investigate the pathology of human pathogens and identify potential targets for novel 
therapeutic drugs. 
 
Drug Design 
 Understanding the fundamental basis of bacterial toxin binding interactions is a 
potentially important factor in the development of inhibitor drugs and vaccines. Cell binding is 
typically the first interaction involved in cellular internalization, which makes it a very attractive 
target for pharmaceutical agents. In addition to inhibiting a toxin in the initial stage of 
intoxication, the extracellular location of toxin binding allows therapies to be effective without 
the added complication of entering cells. One main strategy employed in the development of 
inhibitors as well as vaccines the rational design based on the location and molecular 
composition of a receptor binding site (Tanrikulu et al. 2008, Liu et al. 2004). While inhibition of 
VacA receptor binding would not necessarily kill H. pylori directly, there is substantial evidence 
that suggests that VacA is necessary or H. pylori colonization and persistence (Schmitt et al. 
1994, Salama et al. 2001, Atherton et al. 1995, Kidd et al. 1999).  In this study, characterization 
of the VacA binding pocket defines a conceptual framework for the design of novel therapies 
targeting SM-binding toxins and grants new insight into a never before investigated binding 
motif.  
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H. pylori 
  H. pylori, is a microaerophilic, Gram negative, spiral shaped bacteria that is the only 
known species to persistently colonize the human stomach (Cover et al.2005). While most 
bacteria are killed by the acidic environment of the stomach, H. pylori is able to survive by 
utilizing flagellar motility and chemotaxis to move up a pH gradient toward the gastric mucosa, 
where it buries itself within the mucous, attaches to the gastric epithelia, and produces urease, an 
enzyme that modulates the pH of the colonization site by neutralizing gastric acid through the 
production of ammonia from urea (Cover et al. 2009, Atherton et al. 2009, Schweintizer et al. 
2008, Parsonnet et al. 1995, Schreiber et al. 2004, Kim et al. 2004, Kuwahara et al. 2000).  H. 
pylori then produces a number of factors such as VacA, which serves to remodel the host tissue 
and assist in immune evasion through effects on the gastric epithelium as well as immune cells 
(Stingl et a. 2002).  
  The main outcome of H. pylori infection is chronic inflammation of the gastric 
epithelium. In most cases gastritis persists for the duration of the infection, which without 
treatment often continues for the lifetime of the host. Gastritis is usually subclinical, however, 
and is not often diagnosed, leading to infection rates over 50% worldwide and in excess of 80% 
in developing countries (Cover et al. 2009, Atherton et al. 2009). Despite a lack of acute 
symptoms, 20-30% of H. pylori infections lead to the development of more serious illnesses such 
as peptic ulcer disease, gastric lymphoma, and gastric adenocarcinoma, which is the second 
leading cause of cancer death worldwide, with over 800,000 deaths each year attributed to gastric 
adenocarcinoma (Amieva et al. 2008, Atherton 2006, Tetzlaff et al 2008, Montecucco et al. 
2001).  H. pylori has been classified as a class I carcinogen by WHO and estimates suggest that 
H. pylori infection increases the risk of developing gastric cancer approximately 10 fold (IARC 
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1994). These estimates do not, however, differentiate between the risk associated with each of 
the well-defined H. pylori phenotypes, which suggest that cancer risk is strongly correlated with 
the production and allelic variation in virulence factors such as VacA (Schmitt et al. 1994, 
Salama et al. 2001, Atherton et al. 1995, Kidd et al. 1999). This correlation suggests the 
possibility that H. pylori associated carcinogenicity is at least partly a result of the production of 
toxins such as VacA, rather than a result of infection alone. 
 
VacA  
VacA is produced as a 140 kD protoxin which is cleaved into an 88 kD mature protein. 
VacA is then secreted by a 33-kD C-terminal β-barrel autotransporter domain, which is separated 
from a 55-kD N-terminal domain by a protease-sensitive loop (Fischer et al. 2001) (fig. 1A) 
(Patrice et al. 2012). VacA is secreted into the extracellular space as a soluble protein which can 
oligomerize to form an active anion-selective pore forming toxin (IARC 1994). Evidence of the 
role of VacA in H. pylori virulence comes from the presence of the vacA gene in every H. Pylori 
human isolate, the association of specific VacA alleles with increased risk of developing 
gastroduodenal diseases, the decreased gastric ulceration observed in gerbil models treated with 
vacA knockout strains of H. pylori, and the in vivo treatment of mice models with VacA alone 
causing necrosis and inflammation in the gastric epithelium (Schmitt et al. 1994, Salama et al. 
2001, Atherton et al. 1995, Fischer et al. 2001, Cover et al. 1992). The most visually evident 
activity of VacA and the basis of toxin’s name is the formation of large acidic vesicles in the 
cytoplasm of cells intoxicated in vitro (Tombola et al. 1999). 
 When VacA binds to epithelial cells, individual monomers oligomerize and the toxin is 
inserted into the membrane (Wang et al. 2001) (2A).  The mechanism of VacA internalization 
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has yet to be fully characterized, but it is known that cell entry is dependent on temperature, 
ATP, and actin, but independent of clatherin based vesicle formation (Ogura et al. 2000, Leunk 
et al. 1988). Following internalization, proton pump ATPase activity in the endocytic vesicles 
leads to vesicle acidification (fig. 2B).  VacA anion-selective pore forming activity then causes 
an influx of chloride ions, which neutralizes the vesicle and stimulates further ATPase activity 
(Willlhite et al. 2004, de Bernard et al 1995, Pagliaccia et al. 1998, Telford et al. 1994).  
Membrane permeable weak bases, such as ammonia, then transverse the membrane, are 
protonated in the acidic environment, and are trapped within the vesicle. Increased concentration 
of protonated bases results in hypertonic conditions within the vesicle, causing vesicle swelling 
and vacuole formation within the cytoplasm of cells.  
 This channel-dependent activity is present in several other actions of VacA, including the 
formation of channels in the plasma membrane, which cause the leakage of ions and small 
molecules from the cell, and in the mitochondrial membrane, which leads to a loss of the 
mitochondrial membrane potential (∆Ψ) (Willlhite et al. 2004, Galmiche et al. 200).When ∆Ψ is 
lost, cytochrome C is released, causing the activation of caspase 9 and the initiation of the 
cellular apoptosis pathways (Gebert et al. 2003, Cover et al. 2001). In addition to these VacA 
membrane channel-dependent activities, VacA can influence signaling pathways in a channel-
independent fashion to suppress immune cell activation, resulting in an increase in intracellular 
calcium, or by acting as an adhesin for H. pylori attachment to the gastric epithelia (fig. 2A) 
Cover et al. 2001, Czajkowsky et al. 1999). 
 
 
 
6 
 
Allelic Variation in VacA 
 One major determining factor for VacA functionality is cell specificity, which has been 
shown to change depending on allelic variations in the vacA gene (Iwamoto et al. 1999). The 
vacA gene is largely conserved, but there are 3 regions with substantial allelic diversity. 
Characterization of these regions based on differences in H. pylori virulence and VacA activity 
has led to the identification of three families of allelic variants in the signal sequence (s1 and s2), 
the intermediate region (i1 and i2),  and in the mid-region (m1 and m2) of vacA(fig. 1B) 
(Gangwer et al. 2010).  The signal sequences (s1 and s2) are located within the p33 portion of the 
gene, and differ predominately as a result of the presence of a hydrophilic region consisting of 
12-amino-acid region present in s2 but not s1 toxins. This region is responsible for the absence 
of activity in s2 vacA compared to s1, and has been shown to act as a dominant negative 
mutation, causing a loss of activity in s1 vacA even when the s2 variant is at a fourth of the 
concentration. Further, it has been shown that mutation of this area results in inactive hetero-
oligomeric complexes which are still able to form anion selective channels (McClain et al. 2001; 
Ivie et al. 2008).  
 
  As with the signals sequence, the intermediate (i) region encodes for a portion of the p33 
gene, which has been shown to be important for VacA activity.  The intermediate region is 
classified into i1 (vacuolating) and i2 (non-vacuolating) regions, with i1 strains being shown to 
significantly increase VacA infiltration and inflammation activity compared to vacA i2 strains 
(Rhead et al. 2007, Basso et al. 2008). Interestingly, only s1/m2 strains show i-type variation, 
with s1/m1 and s2/m2 strains exclusively having i1 and i2 strains, respectively, suggesting 
binding activity dependent variations within the intermediate region.  
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 The final region of substantial allelic variation is the middle (m) region, which is located 
within the p55 domain of vacA. The m region of the p55 domain consists of the pathogenic m1 
allele as well as the less pathogenic m2 strain. The corresponding increased cytotoxicity of m1 
vacA in HeLa cells is believed to be indicative of the increased propensity for m1 strains to bind 
to gastric epithelia, cause inflammation, and ultimately increase the susceptibility for developing 
gastric adenocarcinoma in humans infected with H.pylori expressing the m1 allele compared to 
m2 type strains.  
  In an investigation of the cell binding characteristics of m1 and m2 vacA, allelic 
variations within the mid-region have been shown to lead to differences in cell binding as well as 
cell specificity, suggesting that different mid region alleles may have mutations in residues 
determining VacA cell binding  and receptor dependent differences in tissue tropism. Further, it 
has been shown that cellular internalization and tissue tropism are dependent on the middle (m) 
region allele, with m2 strains showing activity in RK-13 cells but not HeLa cells, and the more 
virulent m1 strain showing greater activity in both RK-13 as well as in HeLa cells (Cristina et al. 
1998) (fig. 2A-B).  While it remains possible that m2 vacA has specifically attenuated binding to 
certain cell types, in vivo expression and decreased colonization of m2 vacA knock-out strains, 
suggesting differences in tissue tropism. 
 In addition to the identification of differences in cell binding between middle region m1 
and m2 alleles, there are a number of studies which have indicated that p55 contains the VacA 
cell binding site (1, 36, 48-49) (Jean-Marc et al. 1999; Moll et al. 1995). One experiment 
supporting this hypothesis showed VacA vacuolating activity in cells following the sequential 
addition of p55 followed by p33 subunits of VacA, but no activity when the same domains were 
added in the opposite order (Torres et al. 2005). This hypothesis was further tested by Wang et 
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al. through the development of truncation mutants and the evaluation of mutant vacuolating and 
cell binding activity. Results of this study strongly indicated that the p55 domain played the 
predominant role in cell binding, and further suggested that the c-terminal 100 residues of the 
p55 domain played a critical role in cell binding (Wang et al 2000). While this study provided 
early indications of the role of p55 in cell binding, the study did not account for the loss of 
binding as a result of the removal of progressively larger portions of the VacA gene, which could 
have resulted in cooperative effects rather than the direct contributions of each of the removed 
portions.  
To account for some of the shortcomings of the previous deletion studies, Ivie et al. 
introduced far smaller deletion mutations within the p55 domain of VacA which were limited to 
a single  β-helical turn (Fig. 3A). The adoption of this approach allowed for the analysis of much 
smaller regions of p55 while sumultaniously reducing the probabilty of toxin misfolding 
(Megraud et al. 2004). Analysis of mutant toxins indicated that the most drastic ablation of 
vacuolating activity was observed in mutations Δ559-579, Δ580-607, and Δ608-628, which were 
each hypothesized to be caused by disrupted toxin folding. Each of 3 β-helical turns Δ484-504, 
Δ511-536, and Δ517-544 retained vacuolating activity, indicating that these regions are 
dispensable for VacA activity. Finally, a mutation in the N-terminal region Δ433-461 of VacA 
showed activity in RK13 and AZ521 cells but not in HeLa cells, indicating a region of potential 
receptor specificity (Fig. 3 B-D).  
 Following the discovery that the middle region of VacA played a role in cell binding and 
allele dependent tissue tropism, a number of studies were done to identify which portion of the 
middle region was predominantly responsible for this specificity. To evaluate the effects of m1 
and m2 regions on VacA virulence, chimeric vacA consisting of portions of both the m1 and m2 
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alleles were constructed (fig. 4A-C)(Ji et al. 2000). Once formed, mutant vacuolating activity 
assayed in various cell types suggested that the primary region which determines m1 and m2 
vacA tissue tropism is present within the first 148 amino acids of the p55 middle region, as 
indicated by the loss of activity in HeLa cells present within the m2 substitution mutants PJ2 and 
G27::AB25 mutants.  While the entirety of this region was shown to affect vacuolating activity, 
results indicated that the first 35 amino acids of this region must correspond to the m1 sequence 
to achieve HeLa cell cytotoxicity, as indicated by the complete loss of activity by the PIV6 
mutant. Further, these findings validated the previous theories suggesting that the C-terminal 
portion of the mid-region are not involved in cell binding by showing that  the amino acid from 
657 onwards plays no role in the phenotypic difference between the m1 and m2 vacA. 
 
  To further elucidate the region important for tissue tropism in m1 and m2 strains, 
Skibinski et al. constructed a series of chimeric vacA mutants of m1 vacA with m2 substitutions 
starting from progressively further distance from the n-terminal end of the middle region (Fig. 
4D-F)(Skibinski et al. 2006). Toxin m1 activity was measured using neutral red uptake assays for 
determining the extent of vacuolation in RK13 and HeLa cells when exposed to H. pylori growth 
supernatants. Results showed a much more graded loss of HeLa cell binding than previously 
suggested, indicating that the entire region spanning from amino acid 501 to 696 played an 
important role in m1 HeLa cell phenotype with no one specific region causing a complete loss of 
activity. Knowing that vacA likely has multiple binding site receptors, this result was 
hypothesized to suggest that multiple binding sites may be involved in tissue tropism. A 
secondary non-exclusive possibility is that binding site residues are positioned on multiple β-
sheets which are proximal in physical location, but distal in linear sequence. In addition to 
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understanding the molecular basis of VacA binding by characterizing the binding site of VacA 
with the more virulent m1 phenotype, identification of binding site residues may give insight into 
the molecular basis of differences in toxin cell binding, pathogenicity, and cell specificity 
between VacA m1 and m2 alleles.  
 
Identification of a VacA Cell Receptor  
 Though the numerous activities of VacA are relatively well understood, a thorough 
understanding of VacA cellular receptors has remained elusive,  a factor which is of specific 
interest as a result of the multiple activities of VacA, including its role in adhesin, in stimulating 
inflammation, as well as in inducing vacuolation (Boquet et al. 2012).  Major reasons for the in 
identifying the receptor include multiple receptors present in different cell lines, alternative 
receptor binding characteristics for VacA expressed by different H. pylori strains, or even 
multiple or alterative binding on the same cells in order to mediate alternative VacA activities 
simultaneously.  One of the earliest receptors identified was the epidermal growth factor (EGF) 
as a receptor in HeLa cells. This was achieved through antibody-mediated inhibition of VacA 
cell binding as well as the immunoprecipitation of VacA along with the EGF receptor (Seto et al. 
1998).   
 A second receptor identified was the receptor tyrosine phosphatase (RPTP) beta, which 
was discovered using indirect immunofluorescence and flow cytometry as well as through the 
observation of increased sensitivity in AZ-521 cells following overexpression of RPTP beta 
(Hirayama 2012; Nakayama et al. 2006). Further, studies have shown that RPTPalpha is bound 
by VacA (Yahiro et al. 2004). Consistent with previous evidence suggesting alternative tissue 
tropism of m1 and m2 type VacA, immunoprecepitation experiments in m2 VacA in AZ-521 
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cells showed attenuated binding to RPTP alpha from HeLa cells compared to G401 cells (De 
Guzman et al. 2005). Despite nearly identical amino acid sequence, a slightly increased 
RPTPalpha molecular mass in G401 cells suggested that differences in binding may be a result 
of differences in post-translational modifications. This finding provides even further evidence of 
the complexity of VacA binding and tissue tropism.  
 While EGFR and RPTP are believed to be involved in the cellular vacuolation activity of 
VacA, they do not explain the anti-inflammatory activity of VacA on immune cells. In 2010, 
Sewald et al. identified the immune cell specific receptor CD18 as an m1 VacA receptor in 
leukocytes (Sewald et al.). This was shown through the lack of activity present in CD18 knock 
out leukocytes, as well as through direct immune-precipitation. In addition to identifying CD18 
as the primary receptor for leukocytes, these studies suggested a number of secondary receptors 
involved, which interact with CD18 to form heterodimeric complexes.  Further, these studies 
showed that receptor interactions are specific to human CD18, casting substantial skepticism on 
murine models of H. pylori intoxication.  
 Still other studies suggest that the identity of the high affinity receptor in some cell lines 
is a glycosylphosphatidylinositol (GPI) -anchored protein. Evidence for VacA association with 
GPI-anchored proteins is supported by the attenuation of VacA cell binding following cell 
treatment with phospholipase C (PI-PLC) (Vittorio et al. 2008; Ricci et al. 2000). Upon further 
experiments, however, it was found that VacA binding to cell lipid rafts associated with GPI-
anchored proteins, rather than to the proteins themselves (Schraw et al. 2002). In conjunction 
with the effects of PI-PLC on VacA cell binding, this result suggested that VacA association 
with phospholipids present within ordered domains likely plays an important role in cell binding 
and toxin internalization.  
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 While the protein receptors discussed above are likely the primary receptors for VacA, it 
is known that in addition to specific high affinity m1 type receptors, there is a distinct secondary 
receptor which plays a role in VacA binding (Wen-Ching et al. 2001).  The identification of the 
importance of lipid rafts in VacA binding and internalization along with the effects of PI-PLC 
incubation strongly suggested that a phospholipid may play a role as this secondary receptor for 
VacA. Evaluation of the effects of exogenous lipid addition on VacA vacuolating activity in 
HeLa cells showed increased sensitivity following the addition of sphingomyelin (SM), but no 
alteration in cellular activity following the addition of phosphatidyl choline (PC), 
phosphatidylethanolamine (PE), or phosphatidylinositol (PI) (fig. 5A)(Gupta et al. 2010). 
Further, cleavage of the phosphorylcholine head group of SM by sphingomyelinase C prior to 
intoxication drastically decreased vacuolating activity, suggesting that VacA specifically 
recognizes the phosphorylcholine head group. Activity could, however, be rescued by the 
subsequent addition of exogenous SM to the growth media (fig. 5C). To ensure that this 
attenuation was a result of decreased binding, flow cytometry was used to show that membrane 
binding is dependent on the presence of the SM phosphorylcholine head group, indicating that 
SM is a cell membrane receptor for VacA (fig. 5D). This finding was of additional significance 
because no other known bacterial toxin utilizes SM as a receptor.   
 In addition to determining that SM is a receptor for VacA, it was found that VacA binds 
to PC to a similar extent as SM but does not induce cellular vacuolation, giving further evidence 
that the phosphorylcholine head group present in both SM and PC is important for VacA binding 
(fig. 5B). This conclusion was supported by the fact that ceramide, which has a structure similar 
to SM without the phosphorylcholine head group, does not have increased VacA binding 
compared to other lipids (fig. 6)(Gupta et al. 2010). Further, it was found that VacA SM binding 
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was substantially higher than binding to PE, which contains a phosphoethanolamine head group 
identical to phosphorylcholine except for the substitution of a primary amine in the place of the 
phosphorylcholine quaternary amine. Together these findings suggested that the quaternary 
amine of SM is the most likely molecule involved in VacA phosphorylcholine specific binding. 
SM binding in toxins 
While SM was only recently identified as a receptor for VacA, the involvement of SM in lipid 
rafts and protein trafficking is very well characterized (Bhat et al. 2013). Along with cholesterol, 
SM forms characteristic lipid raft domains in cell membranes which can act as platforms for the 
recruitment and organization of cellular membrane proteins as well as those produced by viral 
and bacterial pathogens. Further, it is known that lipid rafts play an integral role in cellular 
events including membrane transport and signal transduction (Ikonen 2001; Simons and Toomre 
2000). Lipid rafts have also been suggested as the point of entry for a large number of viruses, 
bacteria, and toxins.  
 Among the most thoroughly studied sphingomyelin binding proteins which are believed 
to interact with lipid rafts are those of the actinoporin family, a very well conserved protein 
family expressed in sea anemonies (Alvarez et al. 2009). Like VacA, acitinoporins are 
extracellular pore forming toxins which are known to bind SM on the surface of cells prior to 
oligomerization and membrane insertion. The most well studied members of this family are 
equinatoxin II (EqtII) and sticholysins I (StI) and II (StII) from the sea anemones Actinia equina 
and Stichodactyla helianthus, respectively. Each actinoporin is known to bind individual SM 
molecules through a conserved motif containing aromatic residues Trp-112 and Trp-113.  
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 Since its initial discovery, actinoporins have been found to have sequence homology with 
a multitude of proteins produced by animals and other plants (Kawashima et al. 2003; Gutiérrez-
Aguirre et al. 2006). In each instance, the predominant area of homology was located within the 
C-terminal region known to be involved in SM binding in actinoporins. Further, this region has 
been identified as a membrane binding site with a conserved P-[WYF]-D pattern located within 
an unstructured loop between ordered domains. While this region has been shown to be critical 
for SM binding, it is also know that a secondary cluster of 3 tyrosine residues plays a critical role 
in binding (Zhang et al. 2011).  
As with VacA, Acitinoporins have been previously shown to bind specifically to SM 
without substantial binding to phosphatidylcholine, ceramide, or sphingosylphosphorylcholine, 
indicating specificity for the phosphocholine head group as well as H-bonding amine and 
hydroxyl groups (Bakrac et al. 2008). While it is believed that the quaternary amine is bound 
through cation-π interactions with active site aromatic groups, the means of conveying additional 
specificity had not been investigated until Maula et al. To determine the molecular mechanism of 
this specificity, methylated SM-analogues 2NMeSM and 3OMeSM were used to determine if H-
bonding to active site tyrosine residues was important for toxin SM binding. Results indicated 
that tyrosine residues played a key role in SM binding through H-bonding between phosphate 
oxygens as well as the secondary amine of the SM group (Maula et al. 2013).    
   Another SM binding toxin, lysenin, was identified in the earthworm E. foetida. As with 
VacA and the actinoporin family, lysenin oligomerizes to form a pore through interactions with 
membrane lipid raft domains (Yilmaz et al 2013). Recent studies have shown that lysenin 
undergoes a conformational change, which results in a membrane insertion (De Colibus et al. 
2012). As with the actinoporin family, lysenin contains a SM binding domain and is a pore 
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forming protein targeted to lipid rafts of the cell membrane (Pawel et al. 2011). An investigation 
of the lysenin SM binding site suggested that, as with actinoporins, the phosphorylcholine is 
bound through aromatic interactions and that the phosphate moiety is bound through hydrogen 
bonding with active site residues.  
 Yet another SM binding protein is the pleurotolysin of edible mushroom Pleurotus 
Eryngii. As with the other SM binding toxins, pleurotolysin A2 is an extracellular A/B type pore 
forming toxin which binds SM present within membrane lipid rafts.  PlyA2 contains an aromatic 
cluster which is conserved between all related strains, and tryptophan residues which have been 
shown to be important for cell binding. Further, the pleurotolysin binding site contains a central 
proline residue as well as secondary tyrosine residues believed to play a role in hydrogen 
bonding to the phosphate moiety (Bhat et al. 2013). 
 In addition to toxins produced by eukaryotic organisms, there are several known bacterial 
proteins which bind SM. Among the most thoroughly characterized of these proteins is that 
Sphingomyelinase (SMase) from Bacillus cereus (Bc-SMase) (Ago et al. 2006). Bc-SMase 
contains an aromatic domain which is conserved in proteins from related bacteria including S. 
aureus and from L. ivanovii. Consistent with the trend in other SM binding proteins, these 
aromatic residues are solvent exposed, located in a hydrophobic region believed to interact with 
the membrane, and located in a beta hairpin motif.  Replacement of these conserved aromatic 
residues with alanine through site directed mutagenesis has been shown to result in drastic 
attenuation in activity as well as plasma membrane binding, confirming their role in binding, and 
providing further evidence of the consistent role of aromatic residues in SM binding.   
 
16 
 
Cation-π interactions  
 In the investigation of other SM binding proteins, the emergence of a multitude of 
consistencies within binding site residues suggests a mechanism of binding which is largely 
conserved even between bacteria and complex eukaryotic organisms. Among the most evident of 
these trends is the presence of a cluster of conserved aromatic amino acids, which normally 
contain tryptophan residues.  Further, it is known that many of these proteins achieve SM 
specific binding to membranes which also contain similar phospholipids including PE, PI, and 
PC, a result which suggest that the quaternary amine of SM is the most likely moiety involved in 
VacA phosphorylcholine specific binding. 
Quaternary amines such as that present in the head group of phosphorylcholine are 
cationic molecules regardless of the pH of a solution, making them very good ligands for 
electrostatic binding. In biological systems, one of the most common interactions with 
quaternary amines are strong non-covalent interactions with the electron rich pi system of 
aromatic rings called cation-π bonding (Ji et al. 2000, Doughtry et al. 2007, Schiefner et al. 
2004). Aromatic amino acids provide a surface of negative electrostatic interaction through pi 
orbitals, resulting in a negative charge on the face of an aromatic ring. In order for cation-π 
bonding to occur, this face must be positioned specifically to allow for the appropriate 
orientation for electrostatic interactions to occur (Dogherty et al. 2007). 
Of the aromatic amino acids which play a role in Cation-π interactions, by far the most 
conserved is tryptophan. This is likely a result of the indol ring electrostatic potential being 
substantially larger than that of phenylalanine or tyrosine. These cation-π interactions usually 
occur within a distance of 6 Å and are strongest with tryptophan and phenylalanine residues, but 
17 
 
also occur with the tyrosyl group of tyrosine. While phenylalanine is believed to have a greater 
potential for strong cation-π interactions, the H-bonding capability of tyrosine can frequently 
result in stronger overall binding. Further, when the hydrogen acts as a donor, electrostatic 
interactions substantially increase resulting in greater charge density and stronger cation-π 
bonding (Dogherty et al. 2007).   
Cation-π interactions are a very common form of non-covalent interaction present in 
nearly half of protein complexes and a third of homodimers investigated (Cowley et al. 2005).  
Cation-π binding has been demonstrated using x-ray crystallography to show protein ligand 
interactions. One of the earliest demonstrations of recognition of this type was binding of the 
neurotransmitter acetylcholine by acetylcholine esterase, wherein a quaternary amine group like 
the one in SM is recognized (Doughterty et al. 1990).  Similar interactions have been observed in 
the recognition of both GABA and serotonin (Lummis et al. 2005; Beene et al. 2002)  Cation-π 
interactions have also been shown to play a critical role in sphingomylinase recognition of the 
phosphorylcholine head group specifically (Parrill et al. 2011). 
Though no known bacterial toxin other than VacA uses SM as a cell surface receptor, 
there are proteins such as sphingomyelinase, equinatoxin, and actinoporins that specifically bind 
SM (Beene et al. 2002, Hong et al. 2002, Kiyokawa et al. 2004, Ago et al. 2006, Gallivan et al. 
1999). Using site-directed mutagenesis, the SM-binding site of each of these proteins has been 
characterized. Unsurprisingly, a SM binding motif rich in aromatic amino acids with conserved 
tryptophan residues has been shown to recognize ligands through cation-π interactions.  
Considering the evidence presented above, I hypothesize that: 
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The vacuolating cytotoxin of H. pylori contains a SM binding pocket composed of aromatic 
residues which specifically bind SM through cation-π interactions with the quaternary 
amine of the phosphorylcholine head group of SM. 
 To test this hypothesis, UCSF Chimera molecular modeling software and ClustalW2 
sequence alignment were used to determine regions of structural similarity with other SM 
binding sites as well as amino acid sequence homology with previously characterized SM-
binding proteins. Upon identification of a putative binding site, site-directed mutagenesis was 
used to develop tryptophan to alanine point mutants of residues in each of the VacA domains. An 
E. coli based recombinant expression system was then developed for the independent production 
of the p55 and p33 subunits of VacA. The purified toxin was then screened for the ability to 
induce the formation of cytoplasmic vacuoles in cultured gastric epithelial (AZ521) cells. Two 
attenuated tryptophan mutants were identified within a putative binding site, and the residues 
were then shown to also have attenuated cell binding.  Following initial screens for mutant 
activity, non-tryptophan mutants present in the putative binding site within the middle region of 
p55 were selected for further mutagenesis. Following the screen of mutant vacuolating activity, 
CELISA and SM ELISA will be used to further characterize the putative binding site. Upon the 
completion of this project, this research will provide additional information on the mechanism of 
bacterial toxin SM binding, will be the first study to identify specific residues involved in a 
VacA cell binding site, and will provide the framework for determining if allelic variation in the 
VacA SM-binding site is a determinant in the altered cell specificity and toxin virulence 
observed between VacA mid-region alleles.  
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Chapter 2: Materials and Methods 
Bioinformatics 
 BLAST, ClustalW2, and GeneDoc were used to compare the VacA peptide sequence to 
other VacA alleles as well as sphingomyelin binding proteins equinatoxin II (PDB ID: 2L2B) 
and Bacilus cerus sphingomyelinase (PDB ID: 2DDT). Protein sequences were acquired from 
PubMed protein database and all sequences were compared to the VacA allele present in the H. 
pylori strain 60190 (PDB ID: 2QV3). Molecular modeling was performed using UCSF 
CHIMERA and Swiss-Pdb Viewer. 
Plasmid purification 
Plasmids were purified using a QIAprep Spin Miniprep Kit and the suggested procedure. 
In short, 3 mL of LB media supplemented with 100 ug/mL ampicillin was inoculated with the 
DH5α cells and incubated for 6-12 hrs. Following this incubation, cells were pelleted using a 
table top centrifuge (IEC MicroMax) for 10 min at 5000 x g. The supernatant was then removed, 
the cell pellet was re-suspended in 250 uL P1, and the solution was transferred to a 
microcentrifuge tube.  250 μl Buffer P2 was then added, and the tube was inverted 4–6 times. 
Once the solution was a uniform blue color, 350 μL Buffer N3 was added and mixed 
immediately by inverting the tube 4–6 times. Tubes were then centrifuged for 10 min at 18,000 x 
g. The supernatant present following this spin was then applied to a QIAprep spin column and a 
spun for 1 min at 18,000 x g.  The column was then washed by adding 0.75 mL Buffer PE and 
again spinning down at 18,000 x g for 1 min.  Finally, the column was added to a new centrifuge 
tube and elution buffer, EB, was added and allowed to sit for 1 min. The column was then 
centrifuged for 1 min to remove the eluate, which was stored at 4°C (Figure 8). 
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Site-directed mutagenesis 
 Primers (Table 1) were designed and analyzed for hairpin formation and melting 
temperature using the OligoAnalyzer 3.1 by Integrated DNA Technologies and were synthesized 
by the same company. Lyophilized Primers were suspended in sterile molecular biology grade 
water to an estimated final concentration of 100 nM. PCR was performed using PfuUltra high-
fidelity DNA polymerase (Agilent Technologies) using the suggested protocol. Each 50 mL 
reaction mixtures were made with 5 ρmol of pET20b-vacA-p55 (Fig. 7A; Novagen) containing 
the p55 or p33 vacA insert, 1x Pfu reaction buffer, 250 μM of each dNTP, 2.5 U PfuUltra DNA 
Polymerase (Stratagene), and 100 ρmol of each primer . Sterile molecular grade water was added 
to bring volume to 50 μL , and reactions were performed in sterile, DNase treated, thin-wall PCR 
tubes.  PCR was carried out on a PTC-200 Peltier Thermal Cycler (MJ Research) with the 
following operations:  1)95°C for 2 min, 2) 95°C for 20 s, 3) 42-66 °C for 20 s, 4) 72 °C for 2:15 
min, 5) Go to step 2 18x, 6) 72 °C  for 3 min, 7) 4°C forever, 8) end.  
 Following PCR, 1 μL of 2000 U/mL DpnI (New England Biolabs) was added to each 50 
uL reaction along with5.7 uL 10x Dpn1 buffer. Tubes were then incubated at 37 °C for 3 h to 
degrade methylated template DNA.  PCR products were analyzed using DNA electrophoresis 
with a 0.9% agarose gel. Following electrophoresis, the agarose gel was incubated for 20 min in 
a 100 mL solution of TBE buffer containing 0.5 μg/mL ethidium bromide and DNA was 
visualized using the UV setting on a ChemiDoc XRS Molecular Imager and Quantity One 1-D 
Analysis software (BioRad)(fig. 7B). 
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Transformation 
 Chemically competent E.coli DH5α cells (University of Illinois Cell Media Facility) were 
thawed for 20 min at 4 °C after being stored at -80 °C. 45 uL of competent cells were then added 
to 5 μL of DPN1 digested PCR product. Cells were allowed to incubate with DNA for 5 min at 
42°C, and were then added to a water bath at 42°C for 45 s.  Following heat shock, 1 mL of SOC 
broth was added to each tube and cells were grown in a rotary incubator (Fischer Scientific) at 37 
°C for 90 min.  Cells were then pelleted by centrifugation at 2000 x g for 2 min, were suspended 
in 200 μL SOC media, and were spread on LB plates supplemented with 100 ug/mL ampicillin 
(Sigma) and incubated at 37 °C for 12-16 h. Following incubation, the number of colonies was 
determined and used to calculate transformation efficiency of competent cells. Individual 
colonies were picked with a pipette and used to prepare stock cell lines, which were stored at -80 
C. Plasmids were purified from DH5α cells using the procedure previously discussed.  
Mutants were confirmation by DNA sequencing (Core Sequencing Facility at the 
University of Illinois at Urbana-Champaign). Following sequence conformation, chemically 
competent BL21 cells (University of Illinois Cell Media Facility) were transformed with vector 
DNA using the procedure previously described. Transformants were selected on LB plates 
containing 100 ug/mL ampicillin, and 5 colonies from each plate were used to inoculate 5 mL 
cultures of LB media. Cultures were grown in a rotary incubator until an OD600 of .5 was 
reached. VacA expression was then induced using IPTG at a final concentration of .125 mM and 
cultures were then allowed to grow for an additional 3 hours. 1 mL of each growth was then 
centrifuged at 5000 x g for 10 min using a table top centrifuge (IEC MicroMax), and the pellet 
was re-suspended in SDS PAGE buffer. Tubes were then heated for 5 min at 100 °C and cell 
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lysates were analyzed using SDS-PAGE. Cell lines expressing the greatest amount of 
recombinant protein were used to make stocks that were stored at -80°C (fig. 8A). 
VacA recombinant protein expression and purification 
Cell pellets were removed from -80 °C and re-suspended in 10 mL of a 1% PMSF 
solution made with PBS and lysed using sonication (Fischer Scientific Model: 550 Sonic 
Dismembranator) done with samples on ice. Samples were subjected to 2 rounds of sonication 
consisting of 2 second intervals of sonication followed by 5 seconds without sonication until a 
total sonication time of 3 min was reached. Cell lysates were then centrifuged at 16,000 x g for 
20 min at room temperature to pellet debris. The supernatant containing soluble protein was then 
removed and the remaining pellet, including insoluble VacA within inclusion bodies, was 
solubilized with Buffer B (8 M urea, 0.1 M sodium phosphate buffer, 0.01 M Tris-Cl, pH 8.0).  
Re-suspended inclusion body were then centrifuged at 16,000 x g for 20 min at 4 °C. Following 
centrifugation, supernatant containing recombinant protein was added to 2 mL of Talon metal 
affinity resin (Clontech), which had been previously washed and equilibrated with Buffer B.  The 
protein was allowed to bind the resin for at least 30 min at room temperature or overnight at 4 
°C. 
The resin-protein mixture was then loaded into a column the solution was allowed to flow 
through the column and was collected. Resin was then washed twice with 8 mL of Buffer C (8 M 
urea, 0.1 M sodium phosphate buffer, 0.01 M Tris-Cl, pH 6.3) and the flow through was 
collected.  Protein was then eluted with 4 mL of Buffer D (8 M urea, 0.1 M sodium phosphate 
buffer, 0.01 M Tris-Cl, pH 4.5) and was collected.  Fractions were then analyzed by SDS PAGE 
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and stained with Coomassie brilliant blue to analyze purity. Protein was the quantified using a 
Bradford assay and stored at -80 °C (fig. 8B). 
Refolding of Recombinant VacA 
 Protein was then dialyzed at 4°C using Spectra/Por
®
 membrane (MWCO 6-8,000) for 18 
h with 20x the protein volume of Dialysis Buffer #1 (10 mM Tris-Cl, 1 M urea, 0.1 mM β-
mercaptoethanol, 1 mM L-cysteine, 5% glycerol, pH 11.0).  The protein was then dialyzed with 
fresh Dialysis Buffer #1 for 6 h followed by dialysis with Dialysis Buffer #2 (10 mM Tris-Cl, 0.1 
mM β-mercaptoethanol, 1 mM L-cysteine, 5% glycerol, pH 11.0) for 18 h, fresh Dialysis Buffer 
#2 for another 6 h, Dialysis Buffer #3 (10 mM Tris-Cl, 0.1 mM β-mercaptoethanol, 5% glycerol, 
pH 8.8) for 18 h, and finally with fresh Dialysis Buffer #3 for 6 h.  Debris was pelleted by 
centrifugation at 16,000x g for 20 min at 4°C, and 3 kD pore size Amicon Ultra Centrifugal 
Filter Unit were used to concentrate protein to 2 µM or higher.  Protein was then stored at 4°C. 
Purification of native VacA 
  VacA was produced and purified from H. pylori as previously described (35).  H. pylori 
was grown in BSFB media in culture flasks with 5 µg/mL  vancomycin on a rotary platform 
shaker for 48 h at 37 °C with an atmosphere of 5% CO2. After incubation, H. pylori cultures 
were harvested by centrifugation at 8,000 RPM with a Beckman Coulter Avanti J-E centrifuge 
for 30 min at 4°C. After centrifugation, the supernatant was collected and protein was 
precipitated using 90% ammonium sulfate and overnight incubation at 4°C. Precipitated protein 
was collected by centrifugation at 8,000 RPM for 30 min at 4°C then re-suspended in 10 mM 
phosphate buffer at pH 7.0. Samples were then dialyzed using the Spectra/Por membrane 
(MWCO 50,000) three times into 10 mM phosphate buffer pH 7.0 at 4 °C. After overnight 
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dialysis, the crude concentrated extract was filter sterilized using a 0.2 μm filter. VacA was then 
purified by anion exchange chromatography with Diethyl aminoethyl Sephacel resin (Sigma). 10 
mM phosphate buffer containing 200 mM sodium chloride pH 7.0 was used to elute VacA. All 
eluted fractions were collected and analyzed by SDS-PAGE followed by Coomassie brilliant 
blue staining and immunoblot analysis with rabbit anti-VacA polyclonal antibodies. Fractions 
with the greatest purity were pooled and stored at 4°C until use. 
Visual Vacuolation Assay 
Individual recombinantly expressed VacA subunits (p33 and p55) were mixed in a 1:1 
molar ratio for 1 h at room temperature. Following subunit mixing, pH was lowered to 2.0 
through the addition of 3 M HCl, and samples were incubated for 30 min at 37 . VacA was 
then be neutralized using .3 M NaOH and added to AZ521 cells at concentrations between 1-200 
nM and allowed to incubate for 8 h in MEM (Sigma) supplemented with 2 mM glutamine 
(Sigma), 100 U/mL penicillin(Sigma), 1 mg sulfate/mL streptomycin (Sigma), 10% FBS (JRH 
Biosciences), and 5 mM ammonium chloride (EM Science). Phase contrast microscopy was used 
to count 50 cells in each well to determine the percent of cells containing one or more vacuoles. 
Cell culture  
  AZ-521 cells (3940; Japan Health Science Foundation) were maintained in MEM ( 
Sigma) supplemented with 2 mM glutamine(Sigma), 100 U/mL penicillin(Sigma), 1 mg/mL 
streptomycin (Sigma), and 10% fetal bovine calf serum (FBS; JRH Biosciences). Cells were 
grown at 37 ºC with a 5% CO2 humidified atmosphere. 
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CELISA  
 Recombinant VacA was purified and refolded as previously described. Following 
dialysis, p33 protein concentration was determined using a Bradford assay, and 10 moles of EZ-
Link Sulfo-NHS-LC-Biotin was added to each sample for every 1 mole of p33. The reaction was 
allowed to proceed for 30 min at room temperature, then was halted using Tris hydrochloride at a 
final concentration of 20 mM. Samples were then added to pre-equilibrated dialysis tubes 
(MWCO: 6-8 kD, Spectrum Labs) and dialyzed into PBS (pH 7.4). After 4-6 h, dialysis buffer 
was switched. After another 4-6 h, samples were removed from dialysis and quantified a second 
time using a Bradford Assay.  
Biotinylated p33 was recombined with p55 and acid activated as previously discussed 
then stored at 4  until addition to cells. AZ521 cells were prepared in a 96-well plate until 80% 
confluent, and were removed from growth conditions and placed on ice 30 min prior to the 
addition of VacA.  After 30 min, cells were washed with 200 μL of a 3% BSA solution in PBS, 
and VacA was neutralized with .3 M NaOH at 4  then added to cells PBS (pH 7.4) with 3% 
BSA. After a 30 min incubation at 4 , VacA was removed and cells were washed 3 times with 
PBS (pH 7.4). Cells were then fixed by adding of 100 μL of a 2% paraformaldehyde(sigma), 
0.2% gluteraldehyde (calbiochem), PBS solution (pH 7.4) and allowing the solution to incubate 
for 30 min at room temperature. Cells were then washed 3 times again with a 3% BSA solution 
in PBS. Following washes, streptavidin-HRP (Fisher Scientific) was added to cells with a 
1:15,000 dilution for 30 min at room temperature. After 30 min, cells were washed 3 times with 
200 μL PBS supplemented with 0.1% tween 20 (promega). 100 μL of TMB ultra (Thermo 
Scientific) was then added to each well and samples were incubated at room temperature for 30 
min. Following incubation, 100 μL 2 M sulfuric acid was added to each well containing the 
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TMB ultra. Plates were read with microplate reader (Spectronic 20 Genesys spectrophotometer, 
Sigma-Aldrich) at a wavelength of 450 nm.  
  
27 
 
Chapter 3: Results 
Bioinformatics 
It has been shown previously that VacA binds the phosphorylcholine head group of SM 
and PC preferentially over other sphingolipids and that VacA cell binding to SM on the surface 
of eukaryotic cells is necessary for toxin activity (Gupta et al. 2010). These findings suggest that 
SM acts as a receptor for VacA on the surface of cells and that binding occurs specifically 
through the phosphorylcholine head group. Site-directed mutagenesis has be used in studies with 
other SM binding proteins to show that SM binding occurs through interactions of tryptophan 
and tyrosine rich binding motifs (Hong et al. 2002, Kiyokawa et al. 2004, Ago et al. 2006). As a 
primary method for initially identifying a VacA putative SM binding pocket, the amino acid 
sequence and molecular structure of the previously characterized SM-binding proteins were 
compared to that of VacA in order to determine structural similarities between 
phosphorylcholine binding sites in other proteins and VacA aromatic clusters. 
UCSF chimera based molecular modeling was used to compare the crystal structure of 
the p55 domain of VacA to that of the sphingomyelinase of B. cereus (BC-SMase) as well as the 
eukaryotic pore forming toxins equinatoxin II, an actinoporin-like protein produced by sea 
anemones (Hong et al. 2002), and lysenin, a toxin secreted by the earthworm E. foetida 
(Kiyokawa et al. 2004, Kwiatkowska et al. 2007). Molecular modeling of equinatoxin II 
indicated that the previously identified binding site aromatic residues were located primarily in 
solvent exposed loops connecting β-sheet domains (fig. 9A)(Athanasiadis et al. 2001)(PDB ID: 
1IAZ). A similar binding motif was observed in Bc-SMase (fig. 9B)(Ago et al. 2006)(PDB ID: 
2DDT) with tryptophan, phenylalanine, and tyrosine residues organized in a solvent exposed 
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cluster present on beta hairpins between ordered domains with residues from multiple turns 
contributing to SM binding. Though no crystal structure for lysenin yet exists, predictions of 
secondary structure suggest that a SM binding aromatic cluster is present in turns between β-
sheets (Jamroz et al. 2010) The consistent location of SM binding domains within protein loops 
is likely due to higher solvent exposure for residues within turns as well as increased flexibility 
compared to more structured domains such as α-helicies or β-sheets, allowing for the mobility to 
adopt favorable binding site orientation while interacting with ligands (Shakor et al. 2003). 
Comparison of the structural location of SM binding sites in other proteins suggested that 
the VacA binding site would consist of an aromatic tryptophan containing cluster located in 
solvent exposed loops between ordered domains. The crystal structure of the p55 subunit of 
VacA was examined to determine if a similar motif was present within the p55 domain of VacA 
believed to be responsible for cell binding. Of the 3 tryptophan residues present in p55,  2 were 
found to be located in unstructured surface exposed peptide loops between the β-sheet domains 
which form the core structure of p55 (Fig. 10)(PDB ID: 2Qv3). The tryptophan residues 
identified (W577 and W603) were predicted to be within 3.3 Å of each other and within 14 Å of 
5 other aromatic residues within the mid-region of VacA (Table 2)(Pagliaccia et al. 1998).  
While cation-π interactions normally occur within a range of 6 Å, it is important to consider that 
the large degree of 3-dimensional flexibility present within peptide loops, which likely allows for 
far closer proximity than indicated by the unbound orientation of the VacA crystal structure 
(Kiyokawa et al. 2004).  
Peptide sequence alignment was used to further characterize the similarities between 
other SM binding proteins and VacA through alignment with other SM binding proteins. Though 
no substantial homology was found between VacA and the peptide sequence of Lysenin or BC-
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SMase, a short homologous region was identified between VacA and equinatoxin II, which has 
previously been reported as a conserved phosphorylcholine binding motif present in Actinoporin 
domains present in three animal and two plant phyla (Monastyrnaya et al. 2010, Gutiérrez-
Aguirre et al. 2006) (fig. 11).    
Among the conserved residues within the region homologous to the phosphorylcholine binding 
domain were 3 of the aromatic residues initially hypothesized to be part of the putative VacA SM 
binding site based on three dimensional molecular modeling. Though VacA does not contain the 
exact consensus sequence P-[WYF]-D determined from the sequence alignment of actinoporins-
like proteins, residues are functionally conserved to a large extent (Gutiérrez-Aguirre et al. 
2006). Additionally, there is some variation between the peptide sequences in actinoporins, 
suggesting that there is a degree of latitude in the sequence required for phosphorylcholine 
binding. The lack of significant homology between VacA and the other SM binding proteins was 
unsurprising due to secondary and tertiary structural elements normally playing a more 
substantial role in binding site configuration than primary structure. 
A second sequence alignment based strategy used to identify binding site residues was 
the analysis of the mid-region of different VacA alleles. Previous studies have shown that VacA 
virulence is dependent on mosaicism in the vacA gene (Telford et al. 1994), and that allelic 
variation in the mid-region of vacA leads to changes in toxin cell specificity through alterations 
in cell binding. Pagliaccia et al. demonstrated that m2 strains have decreased virulence in HeLa 
cells compared to m1 strains, but both have comparable activity when VacA of the m2 allele is 
expressed intracellularly (Pagliaccia et al. 1998), suggesting that the differences in cell 
specificity are a result of changes in cell binding. While a far less pronounced attenuation of m2 
VacA activity is observed in RK13 and AZ521 cells, alterations in key SM binding residues 
30 
 
would be a strong indicator of a potential difference in tissue tropism and cellular trafficking 
between middle region alleles.  
Peptide sequence alignment was used to compare m1 and m2 alleles throughout the mid-
region in order to determine if the different activities observed between alleles could be a result 
of mutated aromatic residues and attenuated SM binding in VacA of the m2 subtype (fig. 12). 
Using this technique, 8 aromatic residues were found to consistently vary in the m2 allele 
relative to the m1 subtype (table 2). It was also found that a F555Y allele was consistently 
present, which is notable due to the substantially decreased strength of tyrosine cation-π 
interactions relative to those of tryptophan and phenylalanine (Doughtry 2007). Of the residues 
that were consistently altered in the m2 VacA allele, the aromatic residues F555, Y574, W603, 
and F626 were found to be located within the range of possible cation-π interactions with SM in 
the solvent exposed putative SM binding pocket previously identified (table 2). Notably, it is 
difficult to predict the degree of conformational change during binding or the movement of 
flexible β-helical turn regions, so it is possible that any of the screened residues are involved in 
the same SM binding pocket.  In addition to suggesting a possible location of a SM binding site 
on VacA, this result suggests that attenuation in SM binding may account for some of the 
differences in virulence between vacA alleles as well as the differences in pathogenicity observed 
between H. pylori strains.  
Site-directed mutagenesis 
 To test the hypothesis that the VacA SM binding site is composed of an aromatic cluster 
with tryptophan residues playing and important role, scanning mutagenesis was employed to 
mutate each tryptophan within the p55 and the p33 domain of VacA. Each residue selected was 
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mutated to alanine in order to remove all interactions that are dependent on polar or aromatic 
groups. Following mutagenesis, VacA was produced using a recombinant expression system, 
purified, refolded, and assayed for activity by intoxicating AZ521 cells with mutant and wild 
type toxin.  
 The p33 autotransporter domain of VacA is known to interact with the cell membrane, 
but structural analysis was not performed because no crystal structure exists for this domain. 
Though no structural homology could be identified, the large number of tryptophan residues in 
close proximity to one another within the peptide sequence suggested the possible presence of 
SM binding domains (fig. 13). To test the importance of p33 tryptophan residues for VacA 
activity, each tryptophan within p33 was individually mutated to alanine and the resulting mutant 
proteins were screened for vacuolating activity. The screen of p33 tryptophan residues using 
isual vacuolation assays done using phase contrast microscopy and AZ521 gastric epithelial 
showed that mutation of any of the 8 tryptophan residues within the p33 subunit of VacA led to 
only minor decreases in activity, which were likely a result of minor changes in mutant protein 
structure (fig. 17, table 3).  This finding suggested that the mutation of p33 VacA tryptophan 
residues did not cause substantial attenuation of VacA activity (fig. 14A and 14B). This finding 
was consistent with previous studies, which suggested that the p55 domain of VacA is 
responsible for cell binding, as well as with molecular modeling, which suggested that p55 
contained a putative SM binding site. 
 Unlike the p33 domain, however, the mutation of each of the 3 tryptophan residues in the 
p55 domain led to significant attenuation in vacuolating activity (fig. 14, table 3). As expected, 
mutation of both tryptophan residues present within the putative binding site (W577A and 
W603A) caused significant attenuation in vacuolating activity and resulted in a 4.5 and 7.3 fold 
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attenuation for W577A and W603A, respectively (fig. 14C). Surprisingly, W773A, a mutation 
located in a separate loop between  -sheets, showed a 3-fold attenuation in activity when 
mutated. This finding could indicate the presence of a second SM binding domain, but could also 
be the result of the loss of a secondary activity such as dimerization.  
 Binding site residues were investigated further through site-directed mutagenesis of non-
tryptophan residues proximal to the putative binding site. Considering evidence from molecular 
modeling and sequence alignment of VacA, 10 novel mutants were selected for mutagenesis 
based on their location relative to the putative binding site and homology with other SM binding 
proteins (table 2). In addition to selecting aromatic residues, R552 and K607 were selected for 
mutagenesis based on the possibility of ionic interactions between the positive side groups and 
the negative charge of the phosphorylcholine phosphate group.  So far, 4 of the 10 mutants have 
been screened for activity, and results of visual vacuolation assays indicated that mutation of 
K607A caused a 2 fold attenuation in activity, suggesting that this residue may be involved in 
ionic interactions with the phosphate group of SM (fig. 14D). 
The observation of substantial attenuation in cell activity as a result of a single point 
mutation was consistent with other studies, which showed that removal of complete β-helical 
turns through mutations Δ559-579, Δ580-607, and  Δ608-628 resulted in a full loss of activity 
(Fig. 3A) (Ivie et al. 2010). While Ivie et al. explained this finding by hypothesizing that this 
region was important for protein folding, the present study suggests that attenuation was a result 
of ablated binding activity. Notably, three out of the four mutant residues found to be 
significantly attenuated in this study were located within the Δ559-579 and Δ580-607 β-helical 
turn deletions in this study.  While this finding is consistent with our results, it is notable to 
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observe that improper protein folding in these regions remains a possibility, though this would 
not be expected as a result of a single point mutation.  
Further validation of experimental results comes from prior studies of m1 and m2 
variations within the p55 domain, which here suggested that the major region influencing middle 
region tissue tropism is located within the 35 most N-terminal amino acids of the p55 domain 
(fig. 4)(Ji et al. 2000; Skibinski et al. 2000). In these studies, only modest differences in activity 
were observed for other m1 to m2 substitution mutations in HeLa cells, with no significant 
change observed in RK13 or AZ-521 cells following middle region m1 to m2 substitutions. 
Contrary to these previous results, however, K607A and W603A showed significant decreases in 
activity when mutated, despite having mutations vary similar to those present in m2 VacA. 
While this could possibly be explained by the identity of the amino acids substituted in the m2 
allele, position 603 is an alanine in m2 VacA, as in the present mutation. Position 607 in m2 type 
VacA is a glycine residue. This mutation would not normally be expected to cause large 
differences in activity as a result of the large degree of similarity between glycine and alanine 
residues. These results suggested an alternative phenotype than previously observed.  
 Identification of mutant residues within the putative SM binding site confirmed that these 
tryptophan residues were necessary for toxin activity, but did not directly show that they were 
involved in cell binding. To determine if the attenuated activity observed in the p55 tryptophan 
mutations was a result of decreased cell binding, CELISA binding assays were conducted using 
the p55 mutants W577A and W603A. As suspected, the results of CELISA suggested that the 
attenuation in toxin activity was caused by decreased cell binding. Compared to wild type toxin, 
which had a Kd of 54 nM, W577A and W603A VacA had Kd values of 142 nM and 248 nM, 
respectively (fig. 15). These findings indicate that the putative binding pocket identified in the 
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mid region of the p55 domain of VacA is a cell binding site (Garner et al. 1996). Though the 
mid-region of p55 was previously suspected to contain a VacA binding site, this finding is the 
first to identify specific amino acids involved in cell binding interactions. The attenuated binding 
shown for W603A is of particular significance because this same mutation is present in the less 
virulent m2 vacA allele, suggesting that this single amino acid substitution could largely account 
for the decreased pathogenicity of H. pylori strains expressing this allele (fig. 15).  
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Chapter 4: Conclusions 
 As one of the primary virulence factors and a main determinant in H. pylori associated 
disease risk, understanding the pathology of VacA is of great importance to understanding the 
fundamental cause of H. pylori associated disease (Salama et al. 2001). The identification of 
VacA binding site residues is of particular interest due to the strain associated differences in H. 
pylori virulence that may be a result of deviations in tissue tropism between VacA binding site 
alleles (Iwamoto et al. 1999). Beyond contributing to the understanding of H. pylori 
pathogenicity, a characterized VacA sphingomyelin(SM)-binding site would be the first instance 
of such a binding motif in a bacterial toxin and could serve as a basis for the investigation of 
other systems.  
 In this study, molecular modeling suggested that SM-binding in other proteins occurs 
primarily through tryptophan rich solvent exposed motifs present in unstructured loops between 
ordered domains (fig. 9). A similar putative binding pocket was identified within the mid-region 
of the p55 domain of VacA and molecular distances between aromatic residues within the 
identified aromatic cluster were consistent with the cation-π interactions believed to be 
responsible for binding the quaternary amine present in the phosphorylcholine head group of SM 
(fig. 10, table 2). Further, core residues within the VacA putative SM binding site had substantial 
sequence homology to a previously identified phosphorylcholine binding site in actinoporin-like 
proteins (fig. 11).  
 To elucidate the contribution of the putative binding site residues to VacA cell binding, 
sequence alignment was done using VacA alleles known to have differences in cell binding (fig. 
12). Unsurprisingly, many of the putative binding site residues were mutated in the less virulent 
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m2 VacA allele shown to have attenuated binding to HeLa cells. Beyond supporting the 
hypothesis that the putative binding site is involved in cell binding, this finding suggested that 
the residues identified within the site may represent important differences between alleles and 
could play a role in determining VacA cell specificity. While AZ521 cells are not the most 
sensitive to m1/m2 allelic variation, the investigation of differences in other cell lines presents an 
exciting opportunity for future investigation. 
 In order to test the hypothesis that the SM binding site is composed of a tryptophan rich 
aromatic cluster, scanning mutagenesis was used to mutate all tryptophan residues within VacA. 
Results of vacuolation and CELISA assays showed that mutants of tryptophan residues present 
within the putative binding pocket (W577A and W603A) showed a 4.5 and 7.3 fold attenuation 
in activity, respectively, as well as substantial attenuation in in cell binding (Fig. 14-15). This 
result was of particular significance as a result of W577 being present within a region shown to 
have sequence homology with a known actinoporin phosphorylcholine binding site (Fig. 11).  
To further characterize the putative SM-binding pocket of VacA, 10 new mutants were 
selected based on molecular modeling and sequence comparison (table 2). In addition to residues 
present within the putative binding site, several residues were selected from another aromatic 
cluster on the same face to exclude the possibility of a secondary binding site (fig. 13D). 
Vacuolation assays on the novel mutants suggested that mutation of residues within the 
secondary site did not attenuate toxin activity, but mutation of a positive residue within the 
putative binding site, K607A, led to a 2 fold loss of activity when mutated, suggesting that the 
cationic side chain may be involved in interactions with the negatively charged SM-phosphate 
group (fig. 14).  
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Chapter 5: Future Work 
Recombinant expression systems are a terrific tool for studying mutated proteins, but 
refolded proteins do not always have the same structure as the native form. To confirm that the 
attenuation observed in mutant proteins is not a result of improper folding, protease sensitivity 
assays will be used to show similar degradation profiles between native, wild type recombinant, 
and mutant recombinant proteins. Further confirmation of recombinant protein structure can be 
achieved through the use of circular dichroism to indicate protein secondary structure (Clarke 
2011). In addition to confirming that no improper folding is observed between wildtype and 
recombinant VacA, these same techniques can be used to confirm that point mutations are not 
causing changes in protein folding. Further, it must be shown that the C-terminal His-tag does 
not affect VacA activity. This will be accomplished by measuring the activity of VacA following 
thrombin cleavage of the His-tag. Determining that recombinant proteins have similar structure 
to native VacA and confirming that the His-tag does not affect activity are both important quality 
control steps to ensure that any difference in activity observed is solely a result of induced 
mutations. 
 To further characterize the SM binding site of VacA, additional novel mutants generated 
close to the putative binding pocket will be screened for activity using visual vacuolation assays 
(Table 2). These experiments will further elucidate residues within the binding site which are 
involved in interactions with SM, and results will be used to generate double and triple mutants. 
While a full loss of activity has not yet been observed in mutants, this strategy will allow the 
cumulative contributions of active site residues to be determined. To confirm that any attenuation 
observed is a result of decreased cell binding, CELISA will be performed on each mutant with 
attenuated activity.  While CELISA indicates the extent of cell binding, it is not a direct measure 
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of SM binding. To prove that mutants are attenuated in SM binding, a SM ELISA will be 
performed to directly measure the binding of VacA SM adhered to the surface of a 96-well plate. 
A final CELISA will be done following incubation of cells with varying concentrations of 
sphingomyelinase in order to degrade cell membrane SM, or following the addition of different 
concentrations of exogenous SM in order to determine the dependence of toxin cell binding on 
the presence of membrane SM (Gupta et al. 2010).  
 Along with determining the location of the VacA SM-binding site, the molecular 
interactions involved in this binding will be investigated. Previous studies have shown that 
cation-π interactions often occur between aromatic residues and quaternary amines such as the 
one present on the head group of SM (Doughtry 2007). While data from CELISA and ELISA 
can be used to show that mutants are attenuated in SM binding, tryptophan to alanine mutations 
are not sufficient to conclude that binding occurs through cation-π interactions. To test whether 
or not cation-π interactions are necessary for SM binding, the mutation of binding site residues 
from one aromatic residue to another can be used. This strategy is based on the fact that there are 
distinct differences in the strength of cation-π interactions between aromatic functional groups, 
with tryptophan having the strongest binding followed by phenylalanine and tyrosine (Gallivan 
et al.. 1999). If cation-π interactions are being used in SM binding, then tryptophan and 
phenylalanine to tyrosine mutations of binding site residues will decrease SM binding less than 
the same mutation to alanine. A similar strategy can be employed for determining whether a 
charged group such as the lysine residue K607 is involved in ionic interactions through the 
mutation of this residue to a neutral of acidic amino acid such as glutamate.  
  The finding that several of the mutants identified as a potential part of the putative 
SM binding site (F461, F555, F572, Y574, F594, W603, and F626) are mutated in m2 VacA 
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alleles suggests that changes in the SM binding site may be responsible for allelic variation in 
VacA activity, changes in VacA cell type specificity, as well as differences H. pylori strain 
pathogenicity. AZ-521 cells are not as sensitive to differences between m1 and m2 VacA alleles, 
and subsequent studies of these mutants on alternative cell lines would be of extreme interest. To 
further validate whether these mutations are responsible for the decreased activity and binding 
observed in m2 VacA alleles, site-directed mutagenesis could be used to mutate m1 aromatic 
residues to the m2 analogue amino acid. Following mutagenesis, the cell specific activity can be 
tested using visual vacuolation assays and binding can be tested in wild type and mutant VacA 
using CELISA.  
 Though the VacA SM-binding site has yet to be fully characterized, initial activity and 
binding assays are consistent with structural and sequence alignment based predictions for the 
location of the SM-binding site. The aromatic cluster identified in VacA is the first SM-binding 
site found in a bacterial toxin as well as the first time a cell binding site has been characterized in 
VacA. This finding confirms previous studies that have implicated p55 as the binding domain of 
VacA, gives important structural information about the interaction of VacA with the plasma 
membrane of eukaryotic cells, and provides the first evidence of an actinoporin like 
phosphorylcholine binding site in a bacterial toxin. In addition, this study suggests that 
differences in the SM-binding site between VacA alleles may account for deviations in tissue 
tropism, toxin virulence, and overall pathogenicity between H. pylori strains.  
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Figures and Tables 
 
Figure 1. A. VacA gene organization. VacA is initially expressed as a 140-kD protoxin that is 
cleaved into a mature 88 kD toxin. The 88 kD mature VacA toxin is susceptible to proteolytic 
cleavage, which yields 33 kD and 55 kD putative domains. Each domain is further characterized 
based on hypothesized functional role. B. VacA allelic variation. The vacA gene has 3 main 
regions where substantial diversity is observed, the signal recognition region (s-region), the 
intermediate region (i-region) and the mid-region (m-region). Each regions has a number of 
families of alleles (s1/s2, i1/12/13, and m1/m2), which form mosaic forms of vacA through 
homologous recombination between strains. (Figure adopted from Palframan et al. 2012)   
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Figure 2. A. Multifunctional effects of VacA. The effects of VacA include anion selective 
channel dependent processes including permeabilization of the plasma membrane, causing the 
release of cytosolic factors, permeabilization of the mitochondrial membrane, which leads to the 
release of calcium and cytochrome C, and vacuole formation. VacA also has channel-
independent activities including the stimulation of pro-inflammatory signaling and acting as an 
adhesion for H. pylori attachment to cells. In addition, H. pylori produces a number of factors 
that disrupt the tight junctions between cells and could allow VacA to pass through the epithelial 
barrier to the lamina propria, where it inhibits the activation and proliferation of T lymphocytes 
(Cover et al. 1997, Fiocca et al. 1999, Patal et al. 2002, Szabo et al. 1999, Willhite et al. 2004, 
Galmiche et al. 2000, Gebert et al. 2003) . B. Mechanism of VacA induced vacuole formation. 
Following cell binding, VacA oligomerizes, inserts into the membrane, and uses a clathrin-
independent pathway to enter the cell. As the endocytic vesicle progresses to a late endocytic 
vesicle, VacA begins allowing anions such as chloride to enter the vesicle. The increased anion 
concentration stimulates vacuolar proton pump ATPase activity, which lowers the pH of the 
vacuole (Cover et al. 2001, Czajkowsky et al. 1999).With a decreased pH, membrane permeable 
weak bases such as ammonia are protonated within the vesicle and trapped. The increase in 
concentration of these protonated bases leads to a hypertonic condition within the vesicle and an 
influx of water, which causes swelling of the vesicle and the formation of vacuoles. (Figure 
adopted from Cover, T. and Blanke, S., 2005) 
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Figure 3. A. Diagram of the full-length 88 kDa. Mutations encoding single coil deletions 
within the β-helix of the p55 domain were introduced into the H. pylori chromosomal vacA gene 
by natural transformation and allelic exchange. The relative position of each coil deletion is 
indicated. B-D.Vacuolating cytotoxic activity of mutant proteins. Wild-type H. pylori strain 
60190 and transformed mutant strains were grown in culture. Secreted VacA proteins were 
normalized as described in Methods. Serial two-fold dilutions of VacA-containing preparations 
were added to HeLa cells (B), RK13 cells (C), and AZ-521 cells (D). Neutral red uptake assays 
were used to measure relative vacuolating activity. Results represent the mean ± SD from 
triplicate samples, expressed as a percent of wild-type VacA neutral red uptake. * indicates that p 
≤ 0.02 as determined by Student's t-test compared to wild type VacA. (Figure adopted from Ivie 
et al. 2010) 
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Figure. 4. A. Schematic representation of the constructed chimeras. The shaded boxes show 
replacement of m1 vacA sequence by m2 sequences. Amino acid positions are numbered starting 
from the initiation codon of the vacA gene (11638). Substitution mutations of m1 to m2 
sequences are shown by dark boxes representing these regions. B. Neutral red uptake assays of 
HeLa. Cells were treated with water extracts containing the chimeric VacA proteins. Results of 
the vacuolation of HeLa cells are normalized based on wild type activity. C. Neutral red uptake 
assays of RK13 cells. (parts A-C adopted from Ji et al. 2000) Results of the vacuolation of 
RK13 cells are normalized based on wild type activity D. Schematic representation of 
chimeras. Substitution mutations of m1 to m2 sequences are shown by dark boxes representing 
these regions. The VacA amino acid numbering is based on the initiation codon of the vacA gene 
from strain SPM326. E. Neutral red uptake assay of RK13. HeLa cells treated with growth 
culture supernatants from the VacA chimeric strains concentrated 10-fold using 50% saturated 
ammonium sulfate. Data is normalized to the lowest concentration and are the averages of four 
individual assays. Error bars show standard deviation between assays. F. Neutral red uptake 
assay of RK13. RK13 cell neutral red assays were performed as in part E. above. (parts D-F 
adopted from Skibinski et al. 2000) 
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Figure 5. A. VacA activity increases in the presence of extracellular SM. HeLa cells were 
treated with 200 μM PC, PE, PI, or SM for one hour, then were inoculated with 50 nM VacA and 
incubated for 24 hrs. Cells were then dyed with neutral red and visualized through DIC imaging. 
B. VacA binds to SM and PC preferentially. In brief, the wells of a 96 well plate (costar) were 
coated with 50 μl of phospholipid antigen (50 fmol). Wells were then blocked with PBS 
containing 30% BSA, and were incubated with VacA in PBS with 3% BSA for 2 h at room 
temperature. Wells were then washed with PBS, and bound VacA was detected using  primary 
antibodies diluted 1/1000 with 3% BSA-TBS incubated for 2 h, followed by incubation with 
anti-rabbit IgG bound to streptavidin for an additional 2 h. TMB ultra (Thermo Scientific) was 
then added to each well and samples were incubated at room temperature for 30 min, and 2 M 
sulfuric acid was added to each well. Plates were read with microplate reader (Spectronic 20 
Genesys spectrophotometer, Sigma-Aldrich) at a wavelength of 450 nm. Binding was 
normalized to the percent binding relative to control wells without any lipids. C. The addition of 
extracellular SM following SMaseC incubation rescues VacA activity. HeLa cells were 
pretreated with 100 mU/mL SMase C for 1 h, were washed, and were incubated with 0–200 μM  
SM for 1 hr. Cells were then washed and incubated with 100 nM VacA for 24 hr. Neutral red 
uptake assay was used to measure vacuolation. Asterisks indicate statistically significant 
differences in neutral red uptake. D. Extracellular SM rescues\ lysenin and VacA cell binding 
following SMaseC incubation. HeLa cells were pretreated with 100 mU/mL  SMase C at 37 °C 
and under 5% CO2 for 1 hr. Cells were then washed and chilled to 0 °C. 0–200 μM SM was then 
added and incubated for 1 hr. Cells were then incubated with 10 nM Alexa Fluor 488-labeled 
VacA or 1uM lysenin-GFP at 4 °C. After a 1 hincubation, protein binding was quantified using 
flow cytometry. Asterisks indicate statistically significant differences in VacA binding to cells 
treated with SMase C and mock-pretreated cells. (Figures adopted from Gupta et al., 2010) 
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Figure 6.  Membrane lipid structure. The structure of pertinent membrane lipids were found 
using the lipidomics gateway (http://www.lipidmaps.org/data/structure/). The red arrow indicates 
the site of SMaseC cleavage.  
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Figure 7.  A) Plasmid purification. Purified pET20b-vacA-p55 was run on a 1% agarose gel in 
TBE buffer for 50 min at 100 V. A 1 kb DNA ladder (Promega) was used as a standard, and 
ethidium bromide was used to visualize DNA. Lanes were loaded as follows:1)Y428A, 
2)F461A, 3) F483A, 4)R552A, 5)F555A, 6)Y573A, 7)Y574A, 8)W577A, 9)Y579A,  10)W603A 
, 11)K607A, 12)F626A,  13)W773A ,14)wild type, 15)1kb DNA ladder. B) PCR products of 
site-directed mutagenesis. PCR was performed using PFU-Ultra high fidelity polymerase 
(Agilent Technologies) and desalted primers from Integrated DNA technologies. Purified 
pET20b-vacA-p55 was used as template for each reaction.  PCR products were run on a 1% 
agarose gel in TBE buffer for 50 min at 100 V following a 3 h DNP1 digestion. A 1 kb DNA 
ladder (Promega) was used as a standard, and ethidium bromide was used to visualize DNA.  
Lanes were loaded as follows: 1)W603A , 2)Y428A,  3)Y579A, 4)Y573A, 5)F626A, 6)Y574A, 
7)R552A, 8) F461A , 9)F483A, 10)K607A, 11) F555A, 12) pET20b-vacA-p55 with DPN1 
digest, 13) pET20b-vacA-p55 without DPN1, 14) 1kb DNA ladder. The pET20b-vacA-p55 in 
lane 13 is not representative of normal plasmid purity (Figure 8). 
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Mutation Sequence 
W49A 5’CCCCAGATAAACCCGATAAAGTTGCGCGCATTCAAGCAG 3’ 
 5’CTGCTTGAATGCGCGCAACTTTATCGGGTTTATCTGGGG 3’ 
W80A 5’CCAGTAAGATTGATGGAGGTGCGGATTGGGGGAATGC 3’ 
 5’GCATTCCCCCAATCCGCACCTCCATCAATCTTACTGG 3’ 
W82A 5’GATTGATGGAGGTTGGGATGCGGGGAATGCCGC 3’ 
 5’GCGGCATTCCCCGCATCCCAACCTCCATCAATC 3’ 
W90A 5’GAATGCCGCTACGCATTATGCGATCAAAGGCGGGC 3’ 
 5’GCCCGCCTTTGATCGCATAATGCGTAGCGGCATTC 3’ 
W96A 5’GGATCAAAGGCGGGCAAGCGAATAAGCTTGAAGTGG 3’ 
 5’CCACTTCAAGCTTATTCGCTTGCCCGCCTTTGATCC 3’ 
W225A 5’ GTTAAATTAAATGGCAATGTGGCGATGGGCCGTTTGCAATACG 3’ 
 5’ CGTATTGCAAACGGCCCATCGCCACATTGCCATTTAATTTAAC 3’ 
W283A 5’ GGCACACTGGATTTGGCGCAAAGCGCGGGG 3’ 
 5’ CCCCGCGCTTTGCGCCAAATCCAGTGTGCC 3’ 
W301A 5’CAGGGCTTCTTGGCGCGGGGCTCAAACAAGC 3’ 
 5’GCTTGTTTGAGCCCCGCGCCAAGAAGCCCTG 3’ 
W577A 5’ GTTATAGATGAGTTTTACTATAGCCCTGCGAATTATTTTGACGCTAGG 3’ 
 5’ CCTAGCGTCAAAATAATTCGCAGGGCTATAGTAAAACTCATCTATAAC 3’ 
W603A 5’ CGCTTCTTCAACCCCAGAAAACCCTGCGGGCACATCAAAAC 3’ 
 5’ GTTTTGATGTGCCCGCAGGGTTTTCTGGGGTTGAAGAAGCG 3’ 
W773A 5’ CAAGTATCTTATCGGTAAAGCAGCGAAAAATATAGGCATCAGTAAAACG 3’ 
 5’ CGTTTTACTGATGCCTATATTTTTCGCTGCTTTACCGATAAGATACTTG 3’ 
F555A 5’ CACTAGGTCAATCGCGTCTGGGGGTGTC 3’ 
 5’ GACACCCCCAGACGCGATTGACCTAGTG 3’ 
Y428A 5' CAAGTGGGTGGCGCGGCTTTGGCAGG 3' 
 5’5’ CCTGCCAAAGCCGCGCCACCCACTTG 3’ 
Y579A 5' CCCTTGGAATGCTTTTG CGC  3' 
 5' GCGTCAAAAGCATTCCAAGGG  3' 
Y573A 5' GGT ATAGATGAGTTTGCCTATAGC  3' 
 5' GCTATAGGCAAACTCATCTATAACC  3' 
F626A 5' GCGGTCATGGACTATAGTCAAGCGTCAAATTTAACCATTCAGGGG 3' 
 5’ CCCCTGAATGGTTAAATTTGACGCTTGACTATAGTCCATGACCGC 3' 
Y574A 5' GGTTATAGATGAGTTTTACGCGAGCCCTTGGAATTATTTTG 3' 
 5' CAAAATAATTCCAAGGGCTCGCGTAAAACTCATCTATAACC 3' 
R552A 5' GCGTTTGGAAACTGGCACTGCGTCAATCTTTTCTGGGGG 3' 
 5' CCCCCAGAAAAGATTGACGCAGTGCCAGTTTCCAAACGC 3' 
F461A 5' CAATAACGATATTAGTCTGGGAAGAGCGGTGAATTTAAAGGTGGATGCTCAT 3' 
 5' ATGAGCATCCACCTTTAAATTCACCGCTCTTCCCAGACTAATATCGTTATTG 3' 
F483A 5' GTATTGATACGGGTAATGGTGGTGCGAACACCTTAGATTTTAGTGGTG 3' 
 5' CACCACTAAAATCTAAGGTGTTCGCACCACCATTACCCGTATCAATAC 3' 
K607A 5' CCAGAAAACCCTTGGGGCACATCAGCGCTCATGTTTAATAATCTAACCCTG 3' 
 5' CAGGGTTAGATTATTAAACATGAGCGCTGATGTGCCCCAAGGGTTTTCTGG 3' 
  
Table 1. PCR primers. PCR primers were synthesized by IDT technologies and were analyzed 
for melting temp and the formation of secondary structures using OligoAnalyzer. Primers were 
designed with the mutated codon at the center of each complimentary primer pair.  
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Figure 8. A. p55 expression gel.  BL21 transformed cells were selected for maximum p55 
production following induction with .125 mM IPTG.  Samples were lysed, centrifuged, and 
inclusion bodies were solubilized in an 8 M urea solution. Proteins were run on a 10% 
polyacrylamide gel at 100 V for 1 h with solubilized inclusion bodies (SIB) loaded before the 
soluble cell extract (SCE). (Lane: 1)p55 W461A-1 SIB , 2) p55 W461A-1 SCE, 3)p55 W461A-2 
SIB , 4) p55 W461A-2 SCE, 5)p55 W461A-3 SIB , 6) p55 W461A-3 SCE, 7)p55 W461A-4 SIB 
, 8) p55 W461A-4 SCE, 9)p55 W626A-1 SIB , 10) p55 W626A-1 SCE, 11)p55 W626A-2 SIB 
,12) p55 W626A-2 SCE, 13)p55 W626A-3 SIB , 14) p55 W626A-3 SCE) B. Purification of p55 
and p33 VacA. Cells induced with IPTG and harvested were lysed using sonication, pelleted by 
centrifugation at 16,000 x g for 20 min, and the supernatant containing solubly expressed 
proteins was collected (S lane 1 and 6).  Inclusion bodies containing insoluble VacA were then 
brought into solution by the addition of a Tris buffer (10 mM) containing urea (8 M) and sodium 
phosphate (100 mM). Samples were spun down a second time at 16,000 x g, and supernatant was 
collected (IS lane 2 and 7) and incubated with Talon metal affinity resin overnight at 4 °C. VacA 
bound resin was then added to a gravity flow column and flow through was collected (FT lane 3 
and 8). Beads were then washed with the same buffer at pH 9 (W lane 4 and 9) then eluted with 
buffer at pH 4.0 (E lane 5 and 10). Kaleidoscope (Bio-Rad) protein standard was used as a 
marker in lane 11. Lanes were loaded with samples as follows: 1) p33 S, 2) p33 IS, 3)p33 FT, 
4)p33 W, 5)p33 E, 6)p55 S, 7)p55 IS, 8)p55 FT, 9)p55 W, 10)p55 E, 11) protein standards. 
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Figure 9. Molecular modeling of SM-binding proteins. UCSF chimera 
(http://www.cgl.ucsf.edu/chimera) was used to visualize the crystal structure of SM-binding 
proteins. A. The SM binding site of equinatoxin II. The SM binding site of equinatoxin 2 is 
composed of an aromatic cluster located in a solvent exposed loop between β-sheet domains 
(Kwiatkowska et al. 2007) (PDB ID: 1IAZ). B. The SM binding site of Bc-SMase. As with 
equinatoxin II, the SM binding site of Bc-SMase  is composed of an aromatic cluster in a in 
solvent exposed loop connecting β-sheet domains (Monastyrnaya et al. 2010) )(PDB ID: 2DDT).  
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Figure 10. A. Molecular modeling of the p55 domain of VacA. The crystal structure of VacA 
of the m1 allele from strain 60190 was viewed using UCSF chimera software (PDB ID: 1IAZ) 
(Kwiatkowska et al. 2007).  B. W773 is not located within the putative SM-binding site. 
W773 is located in a loop between ordered domains in a site distinct from the putative SM-
binding site. C. The putative SM-binding site of VacA is a solvent exposed aromatic cluster 
between β-sheet domains. The putative SM binding site of VacA includes residues F555, Y573, 
Y574, W577, W603, and F626, which form an aromatic cluster with residues from several 
solvent exposed loops, as well as R552 and K607, which may be involved in ionic interactions 
with the SM phosphate group. D. A secondary small aromatic cluster is present on a similar 
face as the putative SM-binding site. Aromatic residues Y428, F461, and F48 exist in solvent 
exposed loops between β-sheet domains in a site distinct from the main putative binding site. 
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Figure 11. The VacA putative binding site shares homology with actinoporin-like protein 
SM binding site. This alignment was prepared using GeneDoc 
(http://www.psc.edu/biomed/genedoc). Black shading indicates that amino acids conserved in 
more than 90% of sequences, dark grey shading with light lettering indicate amino acids are 
conserved in more than 60% of sequences, and light grey shading with black letters indicate 
amino acids conserved in more than 40% of sequences. The SM binding domain of actinoporin-
like proteins is characterized by a conserved P-[WYF]-D motif (Jamroz et al. 2010), the majority 
of which is conserved in the mid region of VacA. Residues of interest are indicated include 
Y573, W577, Y579, and F610, which were identified through structural analysis as part of the 
putative SM-binding site. The area with sequence homology to the PC binding motif of 
actinoporins-like proteins is labeled with brackets. 
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Figure 12. Sequence alignment of VacA mid-region. This alignment was prepared using 
GeneDoc (http://www.psc.edu/biomed/genedoc). Black shading indicates that an amino acid is 
conserved in more than 90% of sequences, dark grey shading with light lettering indicate amino 
acids are conserved in more than 60% of sequences, and light grey shading with black letters 
indicate amino acids conserved in more than 40% of sequences. Residues of interest are 
underlined below the sequence and labeled according to the residue number of VacA from strain 
60190. The area with sequence homology to the PC binding motif of actinoporins-like proteins is 
labeled with brackets.  Aligning m1 (m1b:F16 m1a: J99 and 60190) and m2 (Tx30a, OK144, 
OK129) alleles of p55 allowed for the identification of aromatic residues mutated in the less 
virulent m2 strains. Accession numbers at GenBank database with H. pylori corresponding strain 
in parenthesis are: BAJ55469.1(F16),  NC_000921.1(J99), 2qv3(60190), AAA86834.1 (Tx30a), 
BAD51782.1 (OK129), BAD51785.1(OK144). 
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Figure 13. Distribution of VacA tryptophan residues. The p33 subunit (black) contains 8 
tryptophan residues, and the p55 subunit (grey) contains 3 tryptophan residues.  Amino acids are 
numbered in accordance with the mature VacA toxin in H. pylori strain 60190. (Figure modified 
from one made by Matt Pierson) 
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Residue 
Number 
Distance from 
Primary Site 
Consensus m1 
Amino Acid 
Consensus m2 
Amino Acid 
Y428 23.6* Tyr Tyr 
F461 26.3* Phe Ala 
F483 22.5* Phe Leu 
R552 6.0 Arg Ser 
F555 7.4 Phe Tyr 
Y573 13.8 Tyr Tyr 
Y574 11.1 Phe His 
W577 1.7 Trp Trp 
Y579 13.1 Tyr Tyr 
W603 1.7 Trp Ala 
K607 13.2 Lys Gly 
F626 8.2 Phe Asp 
W773 40.3* Trp Trp 
 
Table 2 Distance and homology analysis of non-tryptophan p55 mutants. UCSF chimera was 
used to view the p55 domain of VacA from strain 60190 (PDB ID: 2Qv3). The distance to the 
putative binding site was calculated from the center of aromatic rings or the nucleus of charged 
atoms to a point within the putative binding site equidistant from W603 and W577. Bolded 
residues indicate a difference between m1 and m2 alleles. An asterisk indicates that the residue 
of interest is not within the main putative binding site. Sequence alignments were prepared using 
GeneDoc (http://www.psc.edu/biomed/genedoc) and the sequence of m1 and m2 VacA alleles 
were compared (fig. 12).  
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Figure 14. Visual vacuolation assay of VacA mutants. A. Mutation to W30,W49, W80, and 
W82 does not cause significant attenuation in VacA vacuolating activity. Prior to 
inoculation, individual recombinantly expressed VacA subunits were mixed in a 1:1 ratio for 1 
hat room temperature. Following subunit mixing, .3 M HCl will be used to lower the VacA pH to 
2.0 for 30 min at 37 . VacA was then be neutralized using .3 M NaOH and added to AZ521 
cells at concentrations between 1-200 nM and allowed to incubate for 8 min MEM ( Sigma) 
supplemented with 2 mM glutamine(Sigma), 100 U/mL penicillin(Sigma), 1 mg sulfate/mL 
streptomycin (Sigma), 10% FBS (JRH Biosciences), and 5 mM      . Phase contrast 
microscopy was then used to count 50 cells in each well to determine the percent of cells 
containing one or more vacuoles. B. Mutation to W90,W96, W225, and W283 does not cause 
significant attenuation in VacA vacuolating activity. The protocol described in above was 
used. C. Visual vacuolation assay of p55 W577A, W603A, and W773A. The protocol 
described in above was used. D. Visual vacuolation assay of p55 F461A, F483A, K607A, and 
F626A. The protocol described in above was used. (Figure 14A and B were rendered from data 
acquired by Piotr Karwowski) 
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p55 Mutants  p33 Mutants 
Mutant Vac50 (nM)  Mutant Vac50 (nM) 
native 10  ± 4 
 wild type 
recombinant 
12  ± 4 
F461A 13 ±5  W30A 13 ± 1 
F483A 13± 4  W49A 13 ± 1 
W577A 30 ± 6  W80A 14 ± 1 
W603A 68 ±7  W82A 13 ± 1 
K607A 19 ±3  W90A 14 ± 1 
F626A 14  ± 3  W96A 14 ± 1 
W773A 21 ±4  W225A 19 ± 1 
W603A/W773A 86 ± 13  W283A 20  ± 1 
W577A/W603A 103  ± 12  W225A/W283A 28  ± 4 
 
Table 3. Vac50 Summary. AZ521 were treated as in Fig. 3. Visual analysis of vacuolation was 
performed using a phase contrast microscope. Experiments were done with at least 3 biological 
replicates each done in triplicate. Bold lettering indicates that a significant attenuation was 
observed. (p33 mutant activity reported from data acquired by Piotr Karwowski) 
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Figure 15. CELISA assay of W577A and W603A cell binding. In short, VacA was 
biotinylated then added to cells at 4 °C following recombination and acid activation as in fig. 15. 
Following a 30 min incubation at 4 °C, cells were fixed with 2% paraformaldehyde in PBS for 
30 min, and washed with PBS. Streptavidin-HRP was then added at a 1:15,000 dilution to 
conjugate to biotin bound VacA.  Following additional washes, TMB ultra (Thermo Scientific) 
was added to each well, samples were incubated at room temperature for 30 min, and 2 M 
sulfuric acid was added to each well. Plates were read with microplate reader (Spectronic 20 
Genesys spectrophotometer, Sigma-Aldrich) at a wavelength of 450 nm, and binding was 
normalized based on the signal observed in Native VacA (200 nM). Experiments were done with 
at least 3 biological replicates each done in triplicate. The bold Kd value for p55 W603A VacA 
indicates a statistically significant difference in VacA binding to cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Kd (nM) 
39 
54 
142 
248 
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